Sebastian Maxeiner
Overview
Explore the profile of Sebastian Maxeiner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
326
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xie H, Rutz J, Maxeiner S, Grein T, Thomas A, Juengel E, et al.
Nutrients
. 2024 Mar;
16(5).
PMID: 38474751
Only 20% of patients with muscle-invasive bladder carcinoma respond to cisplatin-based chemotherapy. Since the natural phytochemical sulforaphane (SFN) exhibits antitumor properties, its influence on the adhesive and migratory properties of...
2.
Kamdem M, Zingue S, Grein T, Maxeiner S, Rutz J, Mpho Mmutlane E, et al.
J Ethnopharmacol
. 2023 Oct;
319(Pt 3):117298.
PMID: 37866463
Ethnopharmacological Relevance: Tetrapleura tetraptera (Schumach. and Thonn.) Taub. (Fabaceae) is a tropical plant that is used in Cameroon pharmacopeia for the treatment of many cancers including prostate cancer (PCa), which...
3.
Juengel E, Rutz J, Meiborg M, Markowitsch S, Maxeiner S, Grein T, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835543
Extracts of European mistletoe () are popular as a complementary treatment for patients with many different cancer types. However, whether these extracts actually block bladder cancer progression remains unknown. The...
4.
Bakam B, Ngo Pambe J, Grey T, Maxeiner S, Rutz J, Njamen D, et al.
Environ Toxicol
. 2023 Jun;
38(9):2069-2083.
PMID: 37310102
Despite enormous progress in modern medicine, prostate cancer (PCa) remains a major public health problem due to its high incidence and mortality. Although studies have shown in vitro antitumor effects...
5.
Rutz J, Maxeiner S, Grein T, Sonnenburg M, Khadir S, Makhatelashvili N, et al.
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36232303
Combined cisplatin-gemcitabine treatment causes rapid resistance development in patients with advanced urothelial carcinoma. The present study investigated the potential of the natural isothiocyanates (ITCs) allyl-isothiocyanate (AITC), butyl-isothiocyanate (BITC), and phenylethyl-isothiocyanate...
6.
Xie H, Rutz J, Maxeiner S, Grein T, Thomas A, Juengel E, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230603
Combined cisplatin-gemcitabine (GC) application is standard for treating muscle-invasive bladder cancer. However, since rapid resistance to treatment often develops, many patients turn to supplements in the form of plant-based compounds....
7.
Tsaur I, Thomas A, Monecke M, Zugelder M, Rutz J, Grein T, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35804883
Despite recent advances in the treatment of metastatic prostate cancer (PCa), resistance development after taxane treatments is inevitable, necessitating effective options to combat drug resistance. Previous studies indicated antitumoral properties...
8.
Rutz J, Maxeiner S, Juengel E, Chun F, Tsaur I, Blaheta R
Nutrients
. 2022 Jan;
14(2).
PMID: 35057550
Bladder cancer patients whose tumors develop resistance to cisplatin-based chemotherapy often turn to natural, plant-derived products. Beneficial effects have been particularly ascribed to polyphenols, although their therapeutic relevance when resistance...
9.
Siech C, Rutz J, Maxeiner S, Grein T, Sonnenburg M, Tsaur I, et al.
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053528
Insulin-like growth factor-1 (IGF-1)-related signaling is associated with prostate cancer progression. Links were explored between IGF-1 and expression of integrin adhesion receptors to evaluate relevance for growth and migration. Androgen-resistant...
10.
Juengel E, Schnalke P, Rutz J, Maxeiner S, Chun F, Blaheta R
Biomedicines
. 2021 Nov;
9(11).
PMID: 34829859
Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors predominate as first-line therapy options for renal cell carcinoma. When first-line TKI therapy fails due to resistance development, an optimal second-line therapy...